189 related articles for article (PubMed ID: 31221824)
1. Pharmacological, Mechanistic, and Pharmacokinetic Assessment of Novel Melatonin-Tamoxifen Drug Conjugates as Breast Cancer Drugs.
Hasan M; Marzouk MA; Adhikari S; Wright TD; Miller BP; Matossian MD; Elliott S; Wright M; Alzoubi M; Collins-Burow BM; Burow ME; Holzgrabe U; Zlotos DP; Stratford RE; Witt-Enderby PA
Mol Pharmacol; 2019 Aug; 96(2):272-296. PubMed ID: 31221824
[TBL] [Abstract][Full Text] [Related]
2. Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines.
Treeck O; Haldar C; Ortmann O
Oncol Rep; 2006 Jan; 15(1):231-5. PubMed ID: 16328061
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
[TBL] [Abstract][Full Text] [Related]
4. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway.
Mao L; Yuan L; Slakey LM; Jones FE; Burow ME; Hill SM
Breast Cancer Res; 2010; 12(6):R107. PubMed ID: 21167057
[TBL] [Abstract][Full Text] [Related]
6. Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines.
Kim J; Lee J; Jang SY; Kim C; Choi Y; Kim A
Oncol Rep; 2016 May; 35(5):2553-60. PubMed ID: 26986571
[TBL] [Abstract][Full Text] [Related]
7. Oxyprenylated Phenylpropanoids Bind to MT1 Melatonin Receptors and Inhibit Breast Cancer Cell Proliferation and Migration.
Hasan M; Genovese S; Fiorito S; Epifano F; Witt-Enderby PA
J Nat Prod; 2017 Dec; 80(12):3324-3329. PubMed ID: 29144746
[TBL] [Abstract][Full Text] [Related]
8. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
[TBL] [Abstract][Full Text] [Related]
9. Napabucasin Attenuates Resistance of Breast Cancer Cells to Tamoxifen by Reducing Stem Cell-Like Properties.
Liu X; Huang J; Xie Y; Zhou Y; Wang R; Lou J
Med Sci Monit; 2019 Nov; 25():8905-8912. PubMed ID: 31760402
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer.
Abderrahman B; Maximov PY; Curpan RF; Hanspal JS; Fan P; Xiong R; Tonetti DA; Thatcher GRJ; Jordan VC
Mol Pharmacol; 2020 Oct; 98(4):364-381. PubMed ID: 32788222
[TBL] [Abstract][Full Text] [Related]
12. In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.
Busonero C; Leone S; Bianchi F; Acconcia F
Cell Oncol (Dordr); 2018 Dec; 41(6):677-686. PubMed ID: 30182339
[TBL] [Abstract][Full Text] [Related]
13. Protein arginine N-methyltransferase 2 reverses tamoxifen resistance in breast cancer cells through suppression of ER-α36.
Shen Y; Zhong J; Liu J; Liu K; Zhao J; Xu T; Zeng T; Li Z; Chen Y; Ding W; Wen G; Zu X; Cao R
Oncol Rep; 2018 Jun; 39(6):2604-2612. PubMed ID: 29620287
[TBL] [Abstract][Full Text] [Related]
14. Sustained release of melatonin: A novel approach in elevating efficacy of tamoxifen in breast cancer treatment.
Sabzichi M; Samadi N; Mohammadian J; Hamishehkar H; Akbarzadeh M; Molavi O
Colloids Surf B Biointerfaces; 2016 Sep; 145():64-71. PubMed ID: 27137804
[TBL] [Abstract][Full Text] [Related]
15. The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers.
Kastrati I; Joosten SEP; Semina SE; Alejo LH; Brovkovych SD; Stender JD; Horlings HM; Kok M; Alarid ET; Greene GL; Linn SC; Zwart W; Frasor J
Mol Cancer Res; 2020 Jul; 18(7):1018-1027. PubMed ID: 32245803
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression.
Zhang X; Zhang B; Liu J; Liu J; Li C; Dong W; Fang S; Li M; Song B; Tang B; Wang Z; Zhang Y
Sci Rep; 2015 Feb; 5():7835. PubMed ID: 25644501
[TBL] [Abstract][Full Text] [Related]
17. Anticancer effect of acid ceramidase inhibitor ceranib-2 in human breast cancer cell lines MCF-7, MDA MB-231 by the activation of SAPK/JNK, p38 MAPK apoptotic pathways, inhibition of the Akt pathway, downregulation of ERα.
Vethakanraj HS; Sesurajan BP; Padmanaban VP; Jayaprakasam M; Murali S; Sekar AK
Anticancer Drugs; 2018 Jan; 29(1):50-60. PubMed ID: 29023248
[TBL] [Abstract][Full Text] [Related]
18. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.
Weng SC; Kashida Y; Kulp SK; Wang D; Brueggemeier RW; Shapiro CL; Chen CS
Mol Cancer Ther; 2008 Apr; 7(4):800-8. PubMed ID: 18413793
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of melatonin anticancer effects.
Hill SM; Frasch T; Xiang S; Yuan L; Duplessis T; Mao L
Integr Cancer Ther; 2009 Dec; 8(4):337-46. PubMed ID: 20050373
[TBL] [Abstract][Full Text] [Related]
20. Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer.
Shah KN; Wilson EA; Malla R; Elford HL; Faridi JS
Mol Cancer Ther; 2015 Nov; 14(11):2411-21. PubMed ID: 26333382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
